Circulating sGPVI and D-dimer are increased in patients with AAA and are predictive of AAA status and growth rate in the European cohort. (A-B) Plasma was assessed for sGPVI (A) and D-dimer (B) from healthy older control patients (n = 115), slow-growing AAAs (<2 mm/y; n = 75), or fast-growing AAAs (>2 mm/y; n = 74). The median (25th, 75th percentile) of sGPVI for controls was 14.9 ng/mL (8.7, 34.9), for slow-growing AAAs was 42.2 ng/mL (29.0, 62.7), and for fast-growing AAAs was 102.9 ng/mL (72.9, 132.9), represented by black bars (∗∗∗P < .001, by Kruskal-Wallis test). The median (25th, 75th percentile) of D-dimer for controls was 397.8 ng/mL (310.0, 525.8), for slow-growing AAAs was 779.5 ng/mL (508.7, 1184.9), and for fast-growing AAAs was 948.1 ng/mL (599.5, 1466.1), represented by black bars (∗∗∗P < .001, by Kruskal-Wallis test). (C) The OR and 95% CI for the association between sGPVI and case status (top) and D-dimer and case status (bottom). Both sGPVI and D-dimer were modeled dichotomously (above/below median) and continuously (log base-2 transformed). (D) Unadjusted (blue) and adjusted (red) linear regression for the relationship between sGPVI (n = 149), D-dimer (n = 148), and the growth rate (mm/year) of AAA. Continuous sGPVI and D-dimer are log transformed, analysis restricted to cases only. (E) Comparative ROC curve analysis of sGPVI and D-dimer to distinguish fast- from slow-growing AAA using patients with slow-growing AAAs used as reference, (∗∗∗P < .001, as determined by ROC curve area comparison). (F) The effect of sGPVI adjusted for D-dimer (top) and D-dimer adjusted for sGPVI (middle) on case status was examined using ordinal logistic regression. The combined effect calculated using linear combination of sGPVI and D-dimer (bottom). (G) Unadjusted (blue) and adjusted (red) linear regression for the relationship between sGPVI, D-dimer, and the growth rate (mm/year) of AAA. Continuous sGPVI and D-dimer are log transformed; analysis restricted to cases only (n = 148).